Notify Therapeutics Aps is developing data to support the approval of a drug, to help millions of infertile women worldwide. Approximately ten percent of infertile women suffer from diminished ovarian reserves and for this reason do not benefit from currently available hormonal fertility treatment regimens. For these women, the development of a treatment targeting the very early phase of egg development is a promising solution that may enable them to give birth to a child of their own.
We focus on the activation of so-called dormant follicles – a process that is pivotal for fertile eggs to mature. This early phase of follicle development is independent of hormones, and thus fundamentally different from the hormone-dependent processes that characterize the late maturation phase.
Established in 2021.
